News

Key Drivers of AI Drug Discovery

Where AI Meets Genetics: Accelerating Small Molecule Drug Development

Empress Therapeutics Turns to Human Microbiome to Uncover Targeted Therapies

Translating the Code of Life into Small Molecule Medicines

10 Startups to Watch: Empress Therapeutics Mines Microbial Genomes for Drugs

Metagenomics Revolution: Empress Therapeutics on Drug Discovery Breakthroughs

Emerging Company Profile: Empress Looks To The Body’s Internal Chemistry For Drug Leads

A Bet That the Next Blockbuster May Already Be Inside You

Editor's Pick: Empress Therapeutics

Why Empress Therapeutics Is Mining the Human Metagenome for Novel Therapies

AI-Driven Drug Discovery Straddles the Virtual and the Real

Applying Genetics to Chemistry to Find New Small Molecules

Sourcing Chemistry from Inside Humans

Empress Builds Base for Small-Molecule Innovation

Empress Therapeutics Named a PM360 2023 Innovative Startup

Finding Small Molecule Drugs Encoded in DNA

Harnessing Human Genetics to Discover Co-evolved Small Molecule Medicines

AI in Action Podcast: Jason Park, CEO at Empress Therapeutics

Raising Biotech Podcast: Empress Therapeutics Featuring Jason Park and Jim Collins

Decoding the Genetic Programmes: the Power of Artificial Intelligence

Flagship startup Empress Therapeutics launches to search for small molecule drug leads in microbial DNA

Flagship-launched Empress aims to be a small molecule speedster, with up to 4 INDs over next 2 years

Flagship Startup Emerges to Find Drugs in Promising Hunting Ground—Our Bodies

Flagship's newest startup has an ex-J&J immunologist as head scientist